Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaRD in Waldenstrom's Macroglobulinemia
NCT01470196Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2011
- Primary completion
- Sep 2016
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Oct 2011; status: completed.
02
Drugs
carfilzomib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01470196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01470196.